Eli Lilly and Company (NYSE:LLY) Stock Rating Reaffirmed by Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Eli Lilly and Company (NYSE:LLY) in a report issued on Wednesday, Benzinga reports. Cantor Fitzgerald currently has a $885.00 price target on the stock.

LLY has been the topic of a number of other reports. BMO Capital Markets restated an outperform rating and issued a $1,001.00 price target on shares of Eli Lilly and Company in a research note on Wednesday, July 3rd. JPMorgan Chase & Co. lifted their target price on Eli Lilly and Company from $900.00 to $1,000.00 and gave the stock an overweight rating in a research report on Thursday, July 11th. The Goldman Sachs Group lifted their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a neutral rating in a research report on Thursday, April 11th. Morgan Stanley reiterated an overweight rating and set a $1,023.00 target price on shares of Eli Lilly and Company in a research report on Friday, July 5th. Finally, Erste Group Bank upgraded Eli Lilly and Company from a hold rating to a buy rating in a research report on Wednesday, April 3rd. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of Moderate Buy and a consensus target price of $858.72.

Eli Lilly and Company Stock Down 2.0 %

Eli Lilly and Company stock opened at $804.62 on Wednesday. Eli Lilly and Company has a 1-year low of $446.89 and a 1-year high of $966.10. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. The stock has a market cap of $764.72 billion, a PE ratio of 118.50, a P/E/G ratio of 1.75 and a beta of 0.41. The stock’s fifty day moving average is $870.13 and its two-hundred day moving average is $782.95.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The company had revenue of $8.77 billion for the quarter, compared to analysts’ expectations of $8.94 billion. During the same period last year, the firm earned $1.62 earnings per share. Eli Lilly and Company’s quarterly revenue was up 26.0% on a year-over-year basis. On average, sell-side analysts expect that Eli Lilly and Company will post 13.79 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 0.65%. The ex-dividend date of this dividend is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio is presently 76.58%.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 750 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total value of $614,602.50. Following the sale, the chief accounting officer now owns 7,130 shares of the company’s stock, valued at approximately $5,842,821.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, major shareholder Lilly Endowment Inc sold 2,052 shares of the business’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $809.00, for a total transaction of $1,660,068.00. Following the sale, the insider now owns 98,554,195 shares of the company’s stock, valued at approximately $79,730,343,755. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Donald A. Zakrowski sold 750 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total value of $614,602.50. Following the sale, the chief accounting officer now directly owns 7,130 shares in the company, valued at approximately $5,842,821.10. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,214,704 shares of company stock valued at $1,066,841,316. 0.13% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Eli Lilly and Company

Several institutional investors have recently modified their holdings of the company. HB Wealth Management LLC boosted its stake in shares of Eli Lilly and Company by 7.1% during the 2nd quarter. HB Wealth Management LLC now owns 41,460 shares of the company’s stock worth $37,537,000 after acquiring an additional 2,745 shares in the last quarter. Significant Wealth Partners LLC lifted its stake in Eli Lilly and Company by 22.1% in the 2nd quarter. Significant Wealth Partners LLC now owns 559 shares of the company’s stock valued at $506,000 after buying an additional 101 shares in the last quarter. Valley Brook Capital Group Inc. lifted its stake in Eli Lilly and Company by 7.8% in the 2nd quarter. Valley Brook Capital Group Inc. now owns 1,464 shares of the company’s stock valued at $1,325,000 after buying an additional 106 shares in the last quarter. Wright Investors Service Inc. lifted its stake in Eli Lilly and Company by 28.3% in the 2nd quarter. Wright Investors Service Inc. now owns 3,689 shares of the company’s stock valued at $3,340,000 after buying an additional 813 shares in the last quarter. Finally, Fort Pitt Capital Group LLC lifted its stake in Eli Lilly and Company by 13.5% in the 2nd quarter. Fort Pitt Capital Group LLC now owns 1,307 shares of the company’s stock valued at $1,184,000 after buying an additional 155 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.